Research ExplorerPublicationsp16 upregulation is linked to poor prognosis in ERG negative...

p16 upregulation is linked to poor prognosis in ERG negative prostate cancer

Standard

p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. / Burdelski, Christoph; Dieckmann, Tatsiana; Heumann, Asmus; Hube-Magg, Claudia; Kluth, Martina; Beyer, Burkhard; Steuber, Thomas; Pompe, Raisa; Graefen, Markus; Simon, Ronald; Minner, Sarah; Tsourlakis, Maria Christina; Koop, Christina; Izbicki, Jakob; Sauter, Guido; Krech, Till; Schlomm, Thorsten; Wilczak, Waldemar; Lebok, Patrick.

In: TUMOR BIOL, Vol. 37, No. 9, 09.2016, p. 12655-12663.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Burdelski, C, Dieckmann, T, Heumann, A, Hube-Magg, C, Kluth, M, Beyer, B, Steuber, T, Pompe, R, Graefen, M, Simon, R, Minner, S, Tsourlakis, MC, Koop, C, Izbicki, J, Sauter, G, Krech, T, Schlomm, T, Wilczak, W & Lebok, P 2016, 'p16 upregulation is linked to poor prognosis in ERG negative prostate cancer', TUMOR BIOL, vol. 37, no. 9, pp. 12655-12663. https://doi.org/10.1007/s13277-016-5167-y

APA

Burdelski, C., Dieckmann, T., Heumann, A., Hube-Magg, C., Kluth, M., Beyer, B., Steuber, T., Pompe, R., Graefen, M., Simon, R., Minner, S., Tsourlakis, M. C., Koop, C., Izbicki, J., Sauter, G., Krech, T., Schlomm, T., Wilczak, W., & Lebok, P. (2016). p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. TUMOR BIOL, 37(9), 12655-12663. https://doi.org/10.1007/s13277-016-5167-y

Vancouver

Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B et al. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. TUMOR BIOL. 2016 Sep;37(9):12655-12663. https://doi.org/10.1007/s13277-016-5167-y

Bibtex

@article{ba6c8ce54db94fc98c729b5c5773ed4f,
title = "p16 upregulation is linked to poor prognosis in ERG negative prostate cancer",
abstract = "Altered expression of the p16 tumor suppressor is frequently found in prostate cancer, but its role for tumor development and patient prognosis is disputed. In order to clarify the prognostic role of p16 and to draw conclusions on interactions with key molecular features of prostate cancer, we studied p16 expression in a tissue microarray (TMA) with more than 12,400 prostate cancers and attached clinical, pathological, and molecular data such as ERG status and deletions of 3p13, 5q21, 6q15, and PTEN. p16 immunostaining was absent in non-neoplastic prostate cells but was found in 37 % of 9627 interpretable prostate cancers. Finding p16 expression in 58 % of ERG positive but in only 22 % of ERG negative cancers (p < 0.0001), highlights the known androgen-dependence of both genes. Significant associations between p16 upregulation and tumor phenotype or patient prognosis were strictly limited to the subset of ERG negative cancers. For example, p16 positivity increased from 15 % in Gleason ≤3 + 3 to 38 % in Gleason ≥4 + 4 cancers (p < 0.0001) and was associated with early PSA recurrence (p < 0.0001). p16 upregulation was strongly linked to deletions of PTEN (p < 0.0001), highlighting the interaction of both genes in growth control. In conclusion, p16 upregulation is a strong prognostic factor in ERG negative cancers. The strict limitation of its prognostic impact to a molecularly defined subgroup challenges the concept of molecular prognosis testing without considering molecular subtypes.",
author = "Christoph Burdelski and Tatsiana Dieckmann and Asmus Heumann and Claudia Hube-Magg and Martina Kluth and Burkhard Beyer and Thomas Steuber and Raisa Pompe and Markus Graefen and Ronald Simon and Sarah Minner and Tsourlakis, {Maria Christina} and Christina Koop and Jakob Izbicki and Guido Sauter and Till Krech and Thorsten Schlomm and Waldemar Wilczak and Patrick Lebok",
year = "2016",
month = sep,
doi = "10.1007/s13277-016-5167-y",
language = "English",
volume = "37",
pages = "12655--12663",
journal = "TUMOR BIOL",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "9",

}

RIS

TY - JOUR

T1 - p16 upregulation is linked to poor prognosis in ERG negative prostate cancer

AU - Burdelski, Christoph

AU - Dieckmann, Tatsiana

AU - Heumann, Asmus

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Beyer, Burkhard

AU - Steuber, Thomas

AU - Pompe, Raisa

AU - Graefen, Markus

AU - Simon, Ronald

AU - Minner, Sarah

AU - Tsourlakis, Maria Christina

AU - Koop, Christina

AU - Izbicki, Jakob

AU - Sauter, Guido

AU - Krech, Till

AU - Schlomm, Thorsten

AU - Wilczak, Waldemar

AU - Lebok, Patrick

PY - 2016/9

Y1 - 2016/9

N2 - Altered expression of the p16 tumor suppressor is frequently found in prostate cancer, but its role for tumor development and patient prognosis is disputed. In order to clarify the prognostic role of p16 and to draw conclusions on interactions with key molecular features of prostate cancer, we studied p16 expression in a tissue microarray (TMA) with more than 12,400 prostate cancers and attached clinical, pathological, and molecular data such as ERG status and deletions of 3p13, 5q21, 6q15, and PTEN. p16 immunostaining was absent in non-neoplastic prostate cells but was found in 37 % of 9627 interpretable prostate cancers. Finding p16 expression in 58 % of ERG positive but in only 22 % of ERG negative cancers (p < 0.0001), highlights the known androgen-dependence of both genes. Significant associations between p16 upregulation and tumor phenotype or patient prognosis were strictly limited to the subset of ERG negative cancers. For example, p16 positivity increased from 15 % in Gleason ≤3 + 3 to 38 % in Gleason ≥4 + 4 cancers (p < 0.0001) and was associated with early PSA recurrence (p < 0.0001). p16 upregulation was strongly linked to deletions of PTEN (p < 0.0001), highlighting the interaction of both genes in growth control. In conclusion, p16 upregulation is a strong prognostic factor in ERG negative cancers. The strict limitation of its prognostic impact to a molecularly defined subgroup challenges the concept of molecular prognosis testing without considering molecular subtypes.

AB - Altered expression of the p16 tumor suppressor is frequently found in prostate cancer, but its role for tumor development and patient prognosis is disputed. In order to clarify the prognostic role of p16 and to draw conclusions on interactions with key molecular features of prostate cancer, we studied p16 expression in a tissue microarray (TMA) with more than 12,400 prostate cancers and attached clinical, pathological, and molecular data such as ERG status and deletions of 3p13, 5q21, 6q15, and PTEN. p16 immunostaining was absent in non-neoplastic prostate cells but was found in 37 % of 9627 interpretable prostate cancers. Finding p16 expression in 58 % of ERG positive but in only 22 % of ERG negative cancers (p < 0.0001), highlights the known androgen-dependence of both genes. Significant associations between p16 upregulation and tumor phenotype or patient prognosis were strictly limited to the subset of ERG negative cancers. For example, p16 positivity increased from 15 % in Gleason ≤3 + 3 to 38 % in Gleason ≥4 + 4 cancers (p < 0.0001) and was associated with early PSA recurrence (p < 0.0001). p16 upregulation was strongly linked to deletions of PTEN (p < 0.0001), highlighting the interaction of both genes in growth control. In conclusion, p16 upregulation is a strong prognostic factor in ERG negative cancers. The strict limitation of its prognostic impact to a molecularly defined subgroup challenges the concept of molecular prognosis testing without considering molecular subtypes.

U2 - 10.1007/s13277-016-5167-y

DO - 10.1007/s13277-016-5167-y

M3 - SCORING: Journal article

C2 - 27444279

VL - 37

SP - 12655

EP - 12663

JO - TUMOR BIOL

JF - TUMOR BIOL

SN - 1010-4283

IS - 9

ER -